Advertisement

PAWZ - ETF AI Analysis

Compare

Top Page

PAWZ

ProShares Pet Care ETF (PAWZ)

Rating:66Neutral
Price Target:
$60.00
The ProShares Pet Care ETF (PAWZ) receives a solid overall rating, driven by strong contributions from holdings like Zoetis and Idexx Laboratories. Zoetis stands out for its robust financial performance and raised guidance, while Idexx Laboratories benefits from international growth and innovation. However, weaker holdings such as Freshpet, which faces profitability challenges and potential overvaluation, may slightly weigh on the fund's rating. A key risk factor is the ETF's concentration in the pet care sector, which could limit diversification.
Positive Factors
Strong Geographic Diversification
The ETF invests in companies across seven countries, reducing reliance on any single market.
Balanced Sector Exposure
The fund is spread across health care, consumer cyclical, and consumer defensive sectors, offering resilience during market shifts.
Reasonable Expense Ratio
With a 0.5% expense ratio, the ETF is competitively priced compared to many niche funds.
Negative Factors
Underperforming Top Holdings
Several key positions, including Freshpet and Zoetis, have shown weak year-to-date performance, dragging on returns.
High Concentration in U.S. Market
Over 65% of the fund is invested in U.S. companies, limiting exposure to international growth opportunities.
Recent Performance Volatility
The ETF has experienced mixed short-term performance, with losses over the last three months despite gains year-to-date.

PAWZ vs. SPDR S&P 500 ETF (SPY)

PAWZ Summary

The ProShares Pet Care ETF (Ticker: PAWZ) is an investment fund focused on the growing pet care industry. It tracks the FactSet Pet Care Index, which includes companies involved in pet food, veterinary services, pet insurance, and specialty retailers. Some well-known companies in this ETF are Freshpet and Idexx Laboratories. This ETF might appeal to investors looking for growth opportunities in a niche market driven by increasing pet ownership and spending on pet health and wellness. However, new investors should be aware that the ETF’s performance can fluctuate with changes in consumer spending and trends in the pet care industry.
How much will it cost me?The ProShares Pet Care ETF (PAWZ) has an expense ratio of 0.50%, meaning you’ll pay $5 per year for every $1,000 invested. This is higher than average for ETFs because it is actively managed and focuses on a niche sector, which typically requires more specialized research and management.
What would affect this ETF?The ProShares Pet Care ETF could benefit from rising global pet ownership and increased spending on pet health and wellness, as pets are increasingly treated as family members. However, economic downturns or higher interest rates could negatively impact consumer spending on non-essential pet products and services, and regulatory changes in the healthcare sector might affect key holdings like Idexx Laboratories and Zoetis. The ETF’s global exposure also makes it sensitive to international market conditions and currency fluctuations.

PAWZ Top 10 Holdings

The ProShares Pet Care ETF (PAWZ) is a niche fund focused on the growing pet care industry, but recent performance has been a mixed bag. Idexx Laboratories and CVS Group plc are rising stars, benefiting from strong financial results and innovation-driven growth. Meanwhile, Freshpet and Trupanion are dragging the fund, with bearish trends and valuation concerns weighing on their outlook. The ETF leans heavily into health care and consumer sectors, with a global mix of holdings. Overall, PAWZ offers exposure to a promising theme, though some key names are struggling to keep pace.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
Freshpet11.57%$5.65M$2.70B-63.89%
66
Neutral
Idexx Laboratories11.55%$5.64M$56.66B67.20%
78
Outperform
Chewy8.52%$4.16M$14.03B1.00%
54
Neutral
Zoetis8.50%$4.15M$52.79B-30.95%
70
Outperform
Pet Valu Holdings Ltd.6.00%$2.93MC$1.88B11.35%
63
Neutral
Virbac SA5.14%$2.51M€2.89B1.72%
73
Outperform
Nestlé SA4.86%$2.37MCHF200.72B15.27%
71
Outperform
Merck & Company4.76%$2.32M$215.32B-7.74%
78
Outperform
Pets at Home4.49%$2.19M£933.91M-26.37%
74
Outperform
Trupanion4.25%$2.07M$1.70B-27.40%
62
Neutral

PAWZ Technical Analysis

Technical Analysis Sentiment
Negative
Last Price
Price Trends
50DMA
55.56
Negative
100DMA
56.46
Negative
200DMA
55.38
Negative
Market Momentum
MACD
-0.50
Positive
RSI
43.62
Neutral
STOCH
37.95
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PAWZ, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 55.19, equal to the 50-day MA of 55.56, and equal to the 200-day MA of 55.38, indicating a bearish trend. The MACD of -0.50 indicates Positive momentum. The RSI at 43.62 is Neutral, neither overbought nor oversold. The STOCH value of 37.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PAWZ.

PAWZ Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$48.25M0.50%
66
Neutral
$98.77M0.99%
66
Neutral
$96.60M0.70%
65
Neutral
$96.34M0.47%
57
Neutral
$26.57M0.69%
74
Outperform
$6.60M0.58%
58
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PAWZ
ProShares Pet Care ETF
54.23
-2.10
-3.73%
AGIX
KraneShares Artificial Intelligence & Technology ETF
FTRI
First Trust Indxx Global Natural Resources Income ETF
IBLC
iShares Blockchain and Tech ETF
LOGO
Tidal Trust III Alpha Brands Consumption Leaders ETF
OND
ProShares On-Demand ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement